We only have this paper's title and publication details.
Read it at the sourcegov identifier, NCT04626505.
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Ziltivekimab is a human monoclonal antibody targeting IL-6 ligand, blocking both the classic and trans-signaling pathways and preserving gp130-mediated signaling independently of IL-6. Unlike other IL-6 receptor blocking agents, it does not cause a paradoxical increase in IL-6 or significant lipi...”
Wada et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: